Remicade denials in California external review
In the California DMHC record, independent physician reviewers decided 36 published external-review cases involving Remicadeand overturned the plan’s denial in 61.1%. That is a historical result among cases that reached this program, not a forecast for an individual appeal.
Conditions behind Remicade denials
| Category | Decisions | Overturned |
|---|---|---|
| Crohn's Disease | 11 | 72.7% |
| Ulcerative Colitis | 4 | 25% |
| Sarcoidosis | 3 | 66.7% |
| Ankylosing Spondylitis | 3 | 0% |
| Hidradenitis Suppurativa | 3 | 100% |
What the insurer actually argued
| Reason given | Decisions | Overturned |
|---|---|---|
Medical Necessity The plan said the care wasn’t medically necessary. The most common fight, and the most winnable. | 25 | 60% |
Experimental/Investigational The plan called the treatment unproven. These turn on published evidence, so the appeal is a literature argument. | 11 | 63.6% |
What the reviewers wrote
Where the denial was overturned
Nature of Statutory Criteria/Case Summary: An enrollee has requested reimbursement for Remicade intravenous infusion. The Health Plan has denied this request indicating that the medication at issue was considered investigational for treatment of the enrollee’s ulcerative colitis. Findings: There is support in the medical literature for the medication at issue in this clinical setting. “Until recently, the main goals in the treatment of UC were to temper the symptoms, such as diarrhea, pain, and weight loss, by using mesalazine and steroids. With newer medications, such as immunomodulators (thiopurines) and the biologics-providing blockade of tumor necrosis factor (TNF), the goals of the therapy in UC have changed to long-term remission and mucosal healing.
Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Remicade induction and maintenance infusions. In a systemic review on medical therapies for inflammatory bowel disease, Talley and colleagues found that tumor necrosis factor (TNF) inhibitors, such as infliximab (brand name Remicade), are strongly recommended based on their efficacy at inducing remission in patients with moderate to severely active symptoms. The American Gastroenterological Association’s guidelines for initial treatment of Crohn’s disease recommend using anti-TNF-α drugs, such as infliximab, to induce remission in patients with moderately severe Crohn’s disease that is refractory to other therapies. The guidelines further recommended anti-TNF monotherapy over no therapy or thiopurine monotherapy, and the continued use of anti-TNF drugs to maintain remission.
Where the denial was upheld
Physician 1This is a patient with apparent left-sided chronic ulcerative colitis who has continued symptoms despite topical and systemic therapy with mesalamine preparations. She is said to have been unresponsive to corticosteroids in the past; however, a review of the medical records provided documents no use of prednisone or other corticosteroids since at least the fall of 2003. Imuran was started in September 2003. The treatment notes from December 2003 indicate the patient was in remission and away from steroids. The patient was no longer on Imuran when she presented with a flare-up of her disease in March 2004, which may be an indication the patient will respond to immunomodulator therapy if maintained on the drug. The treatment notes suggest the patient might have had trouble with nausea while on Imuran but this is not clearly documented.
Findings: The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Remicade 5 mg/kg (500 mg) every eight weeks. In a multicenter, randomized, double-blind, 50-week equivalence study, patients with moderate-to-severe active rheumatoid arthritis despite treatment with methotrexate received Avsola or Remicade. The authors concluded that Avsola demonstrated similar efficacy and safety to Remicade with no clinically meaningful differences between the two medications. In addition, in a meta-analysis assessing the impact of switching between reference biologics and biosimilars of tumor necrosis factor inhibitors in rheumatoid arthritis patients, the authors found that switching between approved biologics and biosimilars of tumor necrosis factor inhibitors is efficacious and safe for rheumatoid arthritis.
Figures and quotations on this page come from 42,749 published decisions in the California DMHC Independent Medical Review dataset. These are California external-review outcomes. Other state and federal programs have different eligibility rules, processes, and current availability; the rates here do not transfer to those programs or predict an individual result. Excerpts are quoted verbatim from the public record and describe this treatment generally, not any individual case.
Why plans deny Remicade — and what reviewed cases show
Remicade (infliximab) is FDA-approved for: crohn's disease, including fistulizing disease (adults and children 6 and older); ulcerative colitis (adults and children 6 and older); rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. An on-label indication can be important evidence when a denial frames the requested use as unproven or cosmetic.
Forced switch to an infliximab biosimilar
Multiple infliximab biosimilars are FDA-approved, and many plans now cover only their preferred one. For a new start that's usually workable; for a patient stable on a specific product — especially with a history of immunogenicity or infusion reactions — the switch itself is the clinical question, and the prescriber's documentation of that history is the appeal.
Dose escalation and interval shortening denied
Infliximab dosing in IBD is weight-based and frequently intensified based on drug levels, antibodies, and disease activity. Plans deny the escalated regimen as exceeding limits or as “not medically necessary.” Therapeutic drug monitoring results attached to the appeal turn this from an argument into a data submission.
Site-of-care restrictions on infusions
As with other infused biologics, plans steer infusions away from hospital outpatient departments and deny at non-preferred sites. Prescriber rationale for monitored infusion — reaction history, comorbidities — is what the exception process weighs.
Step therapy behind newer or preferred agents
Some formularies now prefer other mechanisms or subcutaneous products first. Documented history on infliximab, or the fistulizing-disease indication where infliximab's evidence is long-standing, are the counters.
Dose, product, and step-therapy restrictions all run through the exception process: the prescriber's supporting statement (with monitoring data where relevant) triggers mandatory short decision deadlines, and a denial there escalates to independent review.
Evidence cited in overturned Remicade decisions
- Attach therapeutic drug monitoring results (drug levels, antibody status) whenever dose escalation is the issue — objective data is the strongest rebuttal to a quantity-limit denial.
- For biosimilar-switch denials of a stable patient, document infusion-reaction and immunogenicity history and have the prescriber state the risk of switching products.
- Fistulizing Crohn's disease is an explicit FDA-approved indication — cite it when that's the diagnosis.
- Demand the criteria document and confirm a clinician with IBD experience reviewed the file.
The published California record contains 36 external-review decisions involving Remicade; 61.1% were overturned. This historical rate does not predict another case. For the full class-wide picture — step therapy, biosimilar switching, dose caps, and the record for every IBD biologic — see the Crohn’s & colitis biologic appeal guide.
These outcomes describe eligible cases completed through California DMHC’s Independent Medical Review program. They do not estimate the chance that an internal appeal, an external review in another jurisdiction, or your individual case will succeed. Use the record to identify evidence patterns involving Remicade, then check the rights and deadlines that apply to your plan.
SOURCE: CALIFORNIA DMHC INDEPENDENT MEDICAL REVIEW OUTCOMES (CHHS OPEN DATA) · AGGREGATES + DEIDENTIFIED DECISION EXCERPTS/REFERENCE IDS · METHODOLOGY